PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
17036385-9	2006	DMN treatment induced a highly up-regulated expression of TNF-alpha, TGF-beta, TIMP-1, TIMP-2, PDGF-beta, and MMP-2.	Dimethylnitrosamine	0-3	matrix metallopeptidase 2	Rattus norvegicus	110-115	
27991776-4	2017	CPS also suppressed the DMN-induced increases in alpha-SMA, collagen type I, MMP-2, and TNF-alpha.	Dimethylnitrosamine	24-27	matrix metallopeptidase 2	Rattus norvegicus	77-82	
28752795-5	2017	The DMN treatment produced a progressive increase in the plasma markers (aspartate aminotransferase, alanine aminotransferase, total bililbin, hyarulonic acid, and matrix metalloproteinase-2) in 28 days after the first DMN injection.	Dimethylnitrosamine	4-7	matrix metallopeptidase 2	Rattus norvegicus	164-190	
17036385-10	2006	Of these, the gene expression encoding PDGF-beta and MMP-2 was still further enhanced 2 wk after secession of the 4-wk DMN treatment, and was remarkably ameliorated by CGX administration.	Dimethylnitrosamine	119-122	matrix metallopeptidase 2	Rattus norvegicus	53-58	
16042886-11	2005	RESULTS: In the model group the hepatic MMP-2 mRNA expression started to increase 10 days after DMN administration and remained at a much higher level than in the normal group throughout the study period, while TIMP-2 mRNA expression started to be lower than in the normal group 17 days after DMN administration and reached the lowest level on the 28th day.	Dimethylnitrosamine	96-99	matrix metallopeptidase 2	Rattus norvegicus	40-45	
16042886-11	2005	RESULTS: In the model group the hepatic MMP-2 mRNA expression started to increase 10 days after DMN administration and remained at a much higher level than in the normal group throughout the study period, while TIMP-2 mRNA expression started to be lower than in the normal group 17 days after DMN administration and reached the lowest level on the 28th day.	Dimethylnitrosamine	293-296	matrix metallopeptidase 2	Rattus norvegicus	40-45	
16042886-13	2005	TIMP-2/MMP-2 began to be lower by several days than that of the normal group after DMN administration through the remaining study period.	Dimethylnitrosamine	83-86	matrix metallopeptidase 2	Rattus norvegicus	7-12	
15161499-1	2004	OBJECTIVE: To study the role of changes of matrix metalloproteinase-2, 9 (MMP-2, 9) activity in the development of dimethylnitrosamine (DMN)-induced liver fibrosis in rats.	Dimethylnitrosamine	136-139	matrix metallopeptidase 2	Rattus norvegicus	74-79	
15161499-8	2004	RESULTS: The MMP-2, 9 activity (gray value) significantly increased in the 2d and 3d DMN model rats (2d: normal/model group, MMP-2: 54.72+/-4.56/70.76+/-7.63; F = 16.27, P < 0.05; MMP-9: 25.72+/-4.29/51.76+/-15.33, F=13.38, P < 0.05).	Dimethylnitrosamine	85-88	matrix metallopeptidase 2	Rattus norvegicus	13-18	
15161499-8	2004	RESULTS: The MMP-2, 9 activity (gray value) significantly increased in the 2d and 3d DMN model rats (2d: normal/model group, MMP-2: 54.72+/-4.56/70.76+/-7.63; F = 16.27, P < 0.05; MMP-9: 25.72+/-4.29/51.76+/-15.33, F=13.38, P < 0.05).	Dimethylnitrosamine	85-88	matrix metallopeptidase 2	Rattus norvegicus	125-130	
15571005-6	2004	Treatment with dimethylnitrosamine increased transcripts levels for transforming growth factorbeta1, procollagen alpha1(I), tissue inhibitors of metalloproteinase-1 and matrix metalloproteinase-2 by 7-, 7-, 4- and 15-fold, respectively.	Dimethylnitrosamine	15-34	matrix metallopeptidase 2	Rattus norvegicus	145-195	
15161499-1	2004	OBJECTIVE: To study the role of changes of matrix metalloproteinase-2, 9 (MMP-2, 9) activity in the development of dimethylnitrosamine (DMN)-induced liver fibrosis in rats.	Dimethylnitrosamine	115-134	matrix metallopeptidase 2	Rattus norvegicus	43-72	
15161499-1	2004	OBJECTIVE: To study the role of changes of matrix metalloproteinase-2, 9 (MMP-2, 9) activity in the development of dimethylnitrosamine (DMN)-induced liver fibrosis in rats.	Dimethylnitrosamine	115-134	matrix metallopeptidase 2	Rattus norvegicus	74-79	
15161499-1	2004	OBJECTIVE: To study the role of changes of matrix metalloproteinase-2, 9 (MMP-2, 9) activity in the development of dimethylnitrosamine (DMN)-induced liver fibrosis in rats.	Dimethylnitrosamine	136-139	matrix metallopeptidase 2	Rattus norvegicus	43-72